# Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer

> **NCT07371208** · PHASE2 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SKB264

## Key facts

- **NCT ID:** NCT07371208
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-24
- **Primary completion:** 2028-08
- **Final completion:** 2030-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371208, "Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07371208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*